Kura Oncology, Inc. (KURA) Stock Analysis & Investment Frameworks
Kura Oncology, Inc. (KURA) stock analysis on Invetso. Review Kura Oncology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kura Oncology, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Kura Oncology, Inc. Key Financial Metrics
- Market Cap: $889.61M
- Revenue: $67.48M
- ROE: -207.18%
- ROIC: -66.95%
- Dividend Yield: N/A
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology, Inc. Investment Frameworks
Invetso analyzes Kura Oncology, Inc. (KURA) across the following frameworks:
- Kura Oncology, Inc. 10Y Growth Potential
- Kura Oncology, Inc. Scenario Analysis
- Kura Oncology, Inc. Risks & Opportunities
- Kura Oncology, Inc. Economic Moat
- Kura Oncology, Inc. Business Model
- Kura Oncology, Inc. Management
- Kura Oncology, Inc. SWOT Analysis
- Kura Oncology, Inc. Porter's 5 Forces
- Kura Oncology, Inc. PESTLE Analysis
- Kura Oncology, Inc. ESG Analysis